MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
Perceptive Advisors
Finance & Acquisition: Perceptive Advisors
Parents
Perceptive Advisors
Children
2017: T. Rowe Price Associates Inc., led the round, which also included participation from existing investors Fidelity Management & Research Company, Partner Fund Management LP, Warburg Pincus, Perceptive Advisors, and The Vertical Group.
2018: Join Perceptive Advisors And Buy VBI Vaccines At $2 Now - VBI Vaccines (NASDAQ:VBIV)
2018: Others joining Relay’s latest financing include new investors Foresite Capital, Perceptive Advisors, and Tavistock Group. Earlier investors GV, Casdin Capital, BVF Partners, EcoR1 Capital, an affiliate of D. E. Shaw Research, and Alexandria Venture Investments also participated in the round.
2019: Saama Closes $40 Million Financing with Perceptive Advisors to Drive Disruption in Clinical Analytics and Drug Development
2019: The latest series C round included several new backers such as Aisling Capital Management, Pentwater Capital Management and Perceptive Advisors. Poseida’s previous investors—Longitude Capital, Malin Corporation, Vivo Capital and Boxer Capital—also participated.
2020: Earlier investors include Perceptive Advisors, Fidelity Management & Research Company, Janus Henderson Investors, Farallon Capital Management, Rock Springs Capital, Cormorant Asset Management, EcoR1 Capital, Catalio Capital Management, the Colorectal Cancer Alliance, RA Capital Management, T. Rowe Price Associates, American Cancer Society’s BrightEdge Ventures, Sands Capital, Andreessen Horowitz, DCVC, GV (formerly Google Ventures), Kaiser Permanente Ventures, Novartis (NYSE: NVS, Polaris Ventures, Roche’s venture capital arm, Soleus Capital, and former GV head Bill Maris’s Section 32.
2020: Eventide Asset Management and RTW Investments led the round with Perceptive Advisors, Cormorant Capital, Cowen Healthcare Investments, Point72 Asset management, Irving Investors, Ascend Global Investment Fund, Cedars-Sinai Medical Center and Nestlé SA.
2020: Initial financing provided by Perceptive Advisors, RA Capital, Venrock Healthcare Capital Partners, Chinese investor CMG-SDIC Capital, BlackRock, Casdin Capital, Farallon, Logos Capital, Perceptive Advisors, Pfizer Inc., Sphera Healthcare, funds and accounts advised by T. Rowe Price Associates, Inc., Tybourne Capital Management, Vida Ventures, Viking Global Investors and Wellington Management
2020: Investment led by Perceptive Xontogeny Venture Fund (PXV Fund) and included participation from the Perceptive Life Sciences Fund, both of which are managed by Perceptive Advisors. Earlier investors Rapha Capital Management and Barer & Son Capital also invested.
2020: Investors in the firm have invested at least $251 million and include Cobro Ventures, Perceptive Advisors, Cormorant Funds and RTW.
2020: Led by Perceptive Advisors, with participation from existing investors RRE, GV (formerly Google Ventures), Freemark Capital, Rock Springs Capital, Goodgrower and Claritas Capital and benefits consulting firm NFP.
2020: Nautilus raised a $76 million Series B round led by Vulcan Capital, created by late Microsoft co-founder Paul Allen. Bezos Expeditions, along with Perceptive Advisors, Andreessen Horowitz, Madrona Venture Group, and others
2020: Series E investors include Arrowmark Partners, RA Capital Management, Perceptive Advisors, Jmr Capital and Fjord Ventures
2020: The Series B financing was led by Boxer Capital, Cormorant Asset Management, Samsara BioCapital, Janus Henderson Investors, Logos Capital, BVF Partners L.P., Perceptive Advisors and other investors
2020: The Series C round was led by long-standing investors NEA, Meritech Capital Partners and Lightstone Ventures, as well as new lenders, including Perceptive Advisors.
2021: Existing Nautilus investor Perceptive Advisors
2021: IsoPlexis raised $85 million in equity funding plus a $50 million credit facility in its January series D round, which included backing from Perceptive Advisors, Ally Bridge Group, BlackRock and other investors.
2021: RA Capital Management has stepped up to back Icosavax’s ambitions, leading a $100 million round that also attracted the support of investors including Janus Henderson Investors, Perceptive Advisors and Sanofi Ventures.
2021: Series B financing co-led by EcoR1 Capital and Farallon Capital Management, with Avidity Partners, Casdin Capital, GV (formerly Google Ventures), Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, and Woodline Partners LP. Existing investors Atlas Venture, F-Prime Capital, Lonza, Mass General Brigham Ventures, and New Enterprise Associates (NEA) also participated
2021: Series D investments were made by Perceptive Advisors, MSD Capital and Koch Strategic Platforms, as well as by existing investors including Johnson & Johnson Innovation, Decheng Capital, CAVU Ventures, ACME Capital, 2021: Rapid diagnostic service Cue Health lands $235M in new funding
2021: Series D, $168 million led by Deerfield Management Company, Perceptive Advisors, OrbiMed Advisors, Foresite Capital, Avidity Partners, SharesPost100 Fund, Irving Investors and PFM Health Sciences.
2021: The PIPE was led by a $100 million investment from Palihapitiya and $50 million from Hedosophia, as well as commitments from Fidelity Management & Research Company and funds affiliated with Jennison, Senator Investment Group LP, Casdin Capital and Perceptive Advisors.
2021: The series E financing round was led by previous backer Northpond Ventures and joined by Perceptive Advisors
2021: They are backed by leading VC firms Iconiq Capital, Sequoia Capital, Perceptive Advisors, Corner Ventures, LTS Investments, Helena, and Sofina with $183M in Series A, Series B, and Series C funding. :
2022: Blackstone Growth led the round, with participation from earlier investors Northpond Ventures, GV, Perceptive Advisors, Innovatus Capital Partners, and Foresite Capital.
2022: The investors included the likes of EcoR1 Capital, Boxer Capital, Invus, Deerfield Management and Perceptive Advisors, as well as another large institutional investor, but whose identity was not disclosed.
2023: Sands Capital and Omega Funds, both new investors in the company, co-led the financing, which was rounded out with participation from a mix of old and new backers: Marshall Wace, Soleus Capital, Eventide Asset Management, Farallon Capital, Perceptive Advisors, ArrowMark Partners, Pura Vida Investments and certain funds managed by RTW Investments.
2024: Capstan also has major institutional investors who participated in its latest fundraising round, including Forbion, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, OrbiMed, Polaris Partners and Vida Ventures.
2024: The equity round was led by Andreessen Horowitz (a16z) with participation from Perceptive Advisors, and debt financing was provided by Banc of California.
2024: The round was led by Wellington Management. Previous investors Eventide Asset Management LLC, certain funds managed by RTW Investments, Sands Capital, Soleus Capital, Omega Funds, Perceptive Advisors, and Marshall Wace also participated.
2025: The Series A funds come from three prominent venture capital firms: Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage.
Investors: Fidelity Investments, Partner Fund Management, Perceptive Advisors, T. Rowe Price, The Vertical Group, Warburg Pincus
Portfolio Companies: Perceptive Avisors
Jumps
Key People: Perceptive Advisors
Organization & Developments: Perceptive Advisors